Together, our results reveal that SOX2 expression is a clinically relevant feature in early stages of oral tumorigenesis, and provide original evidence of its potential utility as biomarker for oral cancer risk assessment. This evidence concerns the gene SOX2 and lip and oral cavity carcinoma.